Evidence map›Paper›PMID 38565953›Full record

ArticleNature reviews. Drug discovery2024

Novel drug targets in 2023.

Sorin Avram, Liliana Halip, Ramona Curpan, Tudor I Oprea

Abstract readNewsComment
PubMed Publisher
In one paragraph

Article in Nature reviews. Drug discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Structural mechanisms underlying the modulation of CXCR4 by diverse small-molecule antagonists.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Review
  6. Review
  7. Exploring DrugCentral: from molecular structures to clinical effects.Journal of computer-aided molecular design · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Sorin Avram
Liliana Halip
Ramona Curpan
Tudor I Oprea

Funding

Machine Learning Model Validation for AD/ADRDU24CA224370 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI EDWARDS, JEREMY S · 2018 to 2023
$6.4M
NCI NIH HHS U24 CA224370
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug DiscoveryDrug Delivery SystemsDrug DevelopmentHumansMolecular Targeted Therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.